Genmab A/S (GNMSF) Cash from Investing Activities (2021 - 2026)

Genmab A (GNMSF) has 5 years of Cash from Investing Activities data on file, last reported at -$9.0 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 79.07% year-over-year to -$9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$140.0 million (up 96.84% YoY) and the FY2025 annual result came in at -$5.6 billion, down 289.98% from the prior year.
• Cash from Investing Activities climbed to -$9.0 million in Q1 2026, from -$71.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$9.0 million in Q1 2026 to a low of -$1.5 billion in Q2 2024.
• A 4-year average of -$546.8 million and a median of -$185.0 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities tumbled 682.16% — and 2025, when it jumped 98.85%.
• Tracing GNMSF's Cash from Investing Activities over 4 years: stood at -$185.0 million in 2023, then plunged by 682.16% to -$1.4 billion in 2024, then jumped by 95.09% to -$71.0 million in 2025, then surged by 87.32% to -$9.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$9.0 million (Q1 2026), -$71.0 million (Q3 2025), and -$17.0 million (Q2 2025), per Business Quant data.